Clinical Trial Update: A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update covers a Phase 1/2 study of CLN-081 for non-small cell lung cancer with EGFR exon 20 mutations, and the study is currently active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CLN-081

Snippet

Sponsor: Cullinan Therapeutics Inc. | Conditions: Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING